There has been unprecedented success in demonstrating long-term improvements in cardiovascular and renal clinical outcomes as well as survival rates in type 2 diabetes with the modern glucose-lowering agents glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.